USFDA inspection at Emcure Pharmaceuticals Ltd's API facility

The United States Food and Drug Administration ("US FDA") had conducted a current Good Manufacturing Practices ('cGMP') inspection of Company's API manufacturing facility located at M.I.D.C., Kurkumbh, Taluka - Daund, Pune - 413802, Maharashtra, from February 19, 2025 to February 25, 2025. On conclusion of the inspection, the Company received two observations in Form 483.

We are addressing the observations comprehensively and will respond to the US FDA within the stipulated timeframe.

Shares of Emcure Pharmaceuticals Limited was last trading in BSE at Rs. 988.80 as compared to the previous close of Rs. 979.40. The total number of shares traded during the day was 2470 in over 453 trades.

The stock hit an intraday high of Rs. 1009.90 and intraday low of 978.10. The net turnover during the day was Rs. 2465765.00.

Source : Equity Bulls

Keywords

EmcurePharmaceuticals INE168P01015 cGMP Inspection USFDA Form483 APIFacility